Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen® and other emerging targets, today announces the appointment of Stacey ...

Roquette is a family-owned global leader in plant-based ingredients and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 150 countries, ...

NGES 4.0 leverages AI technology to enhance efficiency, refine management, and ensure compliance across various ...

Saw palmetto, a small palm plant native to the southeastern USA, is a mainstay in many elite male enhancement products. The ...

With FedRAMP® High authorization, Ceribell’s secure, cloud-based solution can be adopted across federal healthcare systems, ...

On April 29, 2024, Hydreight announced that it achieved record revenue and filed its audited financial statements for the fiscal year ended December 31, 2023. On March 25, 2024. Hydreight Partners ...

OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop ...

WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of ...

Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be ...

Dimerix Limited (ASX: DXB, “Dimerix”) and Amicus Therapeutics (Nasdaq: FOLD, “Amicus”) today announced that the two companies have entered into an exclusive license agreement for the commercialization ...

BestBrick Medical is a well-established medical distributor with over 30 years of deep-rooted presence in the Taiwanese healthcare market. BestBrick specializes in introducing innovative solutions and ...

Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki ...